
drospirenone-ethinyl estradiol oral brand names and other generic formulations include:
Gianvi (28) Oral, Loryna (28) Oral, Nikki (28) Oral, Ocella Oral, Syeda Oral, Vestura (28) Oral, Yasmin (28) Oral, YAZ (28) Oral, Zarah Oral
ombitasvir-paritaprevir-ritonavir-dasabuvir oral brand names and other generic formulations include:
Viekira Pak Oral
drospirenone-ethinyl estradiol oral and ombitasvir-paritaprevir-ritonavir-dasabuvir oral
drospirenone-ethinyl estradiol oral , ombitasvir-paritaprevir-ritonavir-dasabuvir oral . Either increases toxicity of the other by unspecified interaction mechanism. This combination increases the risk of liver related side effects. Stop ethinyl estradiol-containing medications before starting ombitasvir/paritaprevir/ritonavir, and/or dasabuvir. Restart ethinyl estradiol containing medications 2 weeks after the hepatitis C drug treatment of completed.
drospirenone-ethinyl estradiol oral and ombitasvir-paritaprevir-ritonavir-dasabuvir oral
drospirenone-ethinyl estradiol oral , ombitasvir-paritaprevir-ritonavir-dasabuvir oral . Either increases toxicity of the other by unspecified interaction mechanism. ALT elevations >5 x ULN (including some >20 x ULN) observed in clinical trials when ethinyl estradiol was coadministered with ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Discontinue ethinyl estradiol-containing medications before initiating ombitasvir/paritaprevir/ritonavir, and/or dasabuvir. Restart ethinyl estradiol containing medication ~2 weeks after hepatitis C combination drug regimen completed.
Check for more interactions with the Drug Interaction Checker
Drug Interaction Categories
Contraindicated
Never use this combination of drugs because of high risk for dangerous interaction
Serious
Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed
Significant
Potential for significant interaction (monitoring by your doctor is likely required)
Minor
Interaction is unlikely, minor, or nonsignificant